Chief Operating Officer · RELMADA THERAPEUTICS, INC. (RLMD)

Paul Kelly

FY2025 is the first fiscal year CompBrief holds for Paul Kelly as a named executive officer of RELMADA THERAPEUTICS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$5,289,099

Compensation figures as of the proxy filed April 17, 2026 (DEF 14A).

Paul Kelly compensation by year

RELMADA THERAPEUTICS Summary Compensation Table · the one fiscal year held
In US dollars, as RELMADA THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$499,800
Bonus$1,085,480
All other$375,000
Total$5,289,099

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: RELMADA THERAPEUTICS, INC. DEF 14A filed April 17, 2026, accession 0001213900-26-045192, and prior-year filings. Open the filing on EDGAR.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU7,316,336$6,281,367—
Option350,000—$0.67
Option37,500—$3.37
Option32,836—$2.48

Per the Outstanding Equity Awards at Fiscal Year-End table in RELMADA THERAPEUTICS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

RELMADA THERAPEUTICS’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Sergio TraversaChief Executive Officer$8,892,633
Maged ShenoudaChief Financial Officer$6,091,453
Charles EnceChief Accounting and Compliance Officer$5,497,026
Paul Kelly · this pageChief Operating Officer$5,289,099

The full RELMADA THERAPEUTICS compensation record

free company brief

This page is one person within RELMADA THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order RELMADA THERAPEUTICS's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are RELMADA THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy